ClinicalTrials.gg
Sign In
RecruitingNCT06860646Updated Mar 6, 2025

Myocardial Infarction in the Elderly

An observational study in Myocardial Infarction (MI), sponsored by Ryazan State Medical University. Recruiting at 1 site in Russian Federation. Open to participants aged 75 Years and older. Per ClinicalTrials.gov, last updated 2025-03-06.

Sponsored by Ryazan State Medical University · Observational

From the registry’s dates

  • Started Sep 2020; still recruiting 6 years 2 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
75 Years and older
Sex
All
01

Study summary

An observational registry study of patients aged 75 years and older with an established diagnosis of myocardial infarction, initiated in 2020, with an assessment of clinical, instrumental, demographic and prognostic data. Statistical analysis was performed using the StatTech v. 4.5.0 program (developer - StatTech LLC, Russia). Differences were considered statistically significant at p \<0.05.

02

Conditions studied

  • Myocardial Infarction (MI)
03

In context

Myocardial Infarction

2,270 studies on the registry are indexed under Myocardial Infarction; 371 are open to participants now.

This study's planned enrollment of 1,000 is above the median of 568 across 814 observational studies indexed under Myocardial Infarction.

Browse Myocardial Infarction studies →

Lead sponsor

Ryazan State Medical University is the lead sponsor of 21 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
75 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

patients hospitalized in the State Budgetary Institution of the Ryazan Region "Regional Clinical Cardiology Dispensary" with an established diagnosis of myocardial infarction

Inclusion criteria

  • age 75 years and older, presence of an established diagnosis of myocardial infarction at the time of hospitalization.

Exclusion criteria

Exclusion Criteria:

-

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. all-cause death, myocardial infarction, stroke, unplanned percutaneous coronary

    Time frame: 10 years

07

Study locations

1 of 1 sites recruiting
  • State Budgetary Institution of the Ryazan Region "Regional Clinical Cardiology Dispensary"
    Ryazan, 390026, Russian Federation
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2020 (actual). Primary completion is estimated for Sep 2028, 96 months after the start.

Of 296 non-industry observational studies under Myocardial Infarction, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 140. This study's planned 96 months is above that.

Counting every sponsor, half of 333 studies reached it within 48 months; a quarter within 17 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2025
First posted
Mar 6, 2025
StartActual
Sep 1, 2020
Primary completionEst.
Sep 2028
CompletionEst.
Dec 2030
Last update
Mar 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06860646
Lead sponsor
Ryazan State Medical University
Responsible party
Sponsor
First posted
Mar 6, 2025
Start date
Sep 1, 2020
Primary completion
Sep 2028 (estimated)
Completion
Dec 2030 (estimated)
Last update
Mar 6, 2025

Study contacts

Arzu Arifovna Gurbanova
Contact
gurbanovaarzu2@gmail.com
+79065434452
Professor Pereverzeva, Doctor of Medical Sciences
Contact
pereverzevakg@gmail.com
+79209945558

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Myocardial Infarction →

Other studies from this sponsor

Ryazan State Medical University

Start the discussion